bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Sep 3, 2025 · CIK: 1712762
Sentiment: neutral
Topics: 8-K, SEC Filing, Financials
Related Tickers: BIAF
TL;DR
BIAF filed an 8-K on Sept 3, 2025, likely with financial updates.
AI Summary
On September 3, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific dollar amounts or new events were detailed in the provided excerpt.
Why It Matters
This 8-K filing signals that bioAffinity Technologies, Inc. is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report without immediate indication of significant positive or negative developments.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- September 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
FAQ
What specific "Other Events" are reported in this 8-K filing by bioAffinity Technologies, Inc.?
The provided excerpt of the 8-K filing does not detail the specific "Other Events" beyond listing the item category.
What is the significance of bioAffinity Technologies, Inc. filing an 8-K on September 3, 2025?
An 8-K filing signifies that bioAffinity Technologies, Inc. is reporting material events or changes that are of importance to shareholders and the public, as required by the SEC.
Where are bioAffinity Technologies, Inc.'s principal executive offices located?
bioAffinity Technologies, Inc.'s principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
What is the Commission File Number for bioAffinity Technologies, Inc.?
The Commission File Number for bioAffinity Technologies, Inc. is 001-41463.
What is the fiscal year end for bioAffinity Technologies, Inc.?
The fiscal year end for bioAffinity Technologies, Inc. is December 31 (1231).
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-09-03 16:30:32
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 16KB
- ex99-1_001.jpg (GRAPHIC) — 38KB
- ex99-1_002.jpg (GRAPHIC) — 20KB
- 0001641172-25-026403.txt ( ) — 352KB
- biaf-20250903.xsd (EX-101.SCH) — 4KB
- biaf-20250903_def.xml (EX-101.DEF) — 26KB
- biaf-20250903_lab.xml (EX-101.LAB) — 36KB
- biaf-20250903_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 3, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-